Artiva Biotherapeutics (ARTV) Receivables - Net (2023 - 2024)
Artiva Biotherapeutics (ARTV) posted quarterly Receivables - Net of $569000.0 for Q3 2024, little changed quarter-over-quarter from $569000.0 in Q2 2024.
Artiva Biotherapeutics (ARTV) Receivables - Net (2023 - 2024) Analysis & Trends
Artiva Biotherapeutics (ARTV) has reported Receivables - Net for 2 consecutive years, with $569000.0 the latest figure, recorded in Q3 2024.
- In Q3 2024, Receivables - Net changed N/A year-over-year to $569000.0; the TTM figure through Sep 2024 stood at $569000.0 (changed N/A YoY), while the FY2023 annual figure was $1.0 million, changed N/A from the prior year.
- Receivables - Net steadied at $569000.0 in Q3 2024 per ARTV's latest filing, from $569000.0 in the prior quarter.
- Across five years, Receivables - Net topped out at $1.0 million in Q4 2023 and bottomed at $569000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Artiva Biotherapeutics | 451.28 Mn | 451.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 569,000.00 |
| Sep 30, 2024 | 569,000.00 |
| Jun 30, 2024 | 569,000.00 |
| Jun 30, 2024 | 569,000.00 |
| Dec 31, 2023 | 1.03 Mn |
| Dec 31, 2023 | 1.03 Mn |